Genprex Shares Jump 14% Pre-Market on FDA Fast Track Designation

By Ben Glickman

Shares of Genprex were higher early Wednesday after the company said it had received Fast Track Designation from the U.S. Food and Drug Administration for one of its therapies.

The stock rose 14% to 84 cents in pre-market trading. As of Tuesday's close, shares are down about 53% year to date.

The Austin, Texas-based gene therapy company said the FDA had given its lead drug candidate, Reqorsa Immunogene Therapy, Fast Track Designation, which is given to treatments that may address conditions that are serious or life threatening.

Genprex said it expects to enroll patients in its Phase 1/2 clinical response study in the third quarter. The company has studied the use of Reqorsa to treat patients with small cell lung cancer.

Genprex previously received two FDA Fast Track Designations for using Reqorsa in combination with other drugs to treat forms of cancer. The latest designation is for using Reqorsa in combination with Tecentriq, a drug made by Genentech.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

June 28, 2023 09:33 ET (13:33 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.